Condition: IgA Nephropathy · Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.
This description comes directly from the study's public registry record.
Otsuka Call Center · 844-687-8522 · Otsuka-ProfessionalServices@otsuka-us.com
Always discuss trial participation with your own doctor first.
| Clinical Research Site 330 | Denver, Colorado, United States | Recruiting |
| Clinical Research Site 369 | Boston, Massachusetts, United States | Recruiting |
| Clinical Research Site 374 | Dakota Dunes, South Dakota, United States | Recruiting |
| Clinical Research Site 324 | Houston, Texas, United States | Recruiting |
| Clinical Research Site 305 | Scarborough Village, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06740526